Skip to main content
Top
Published in: Abdominal Radiology 2/2016

01-02-2016

CT imaging of early local recurrence of pancreatic adenocarcinoma following pancreaticoduodenectomy

Authors: Clémence Balaj, Ahmet Ayav, Alexandre Oliver, François Jausset, Caroline Sellal, Michel Claudon, Valérie Laurent

Published in: Abdominal Radiology | Issue 2/2016

Login to get access

Abstract

Purpose

The objectives of this retrospective study were to describe the characteristics and topography of pancreatic ductal adenocarcinoma and its early local recurrence after pancreaticoduodenectomy and identify predictive factors of local early recurrence by imaging computed tomography (CT).

Methods

The institutional review board approved the study and did require additional informed consent for reviewing the patients’ medical records and images. Patients who underwent pancreaticoduodenectomy for ductal adenocarcinoma, a preoperative CT scan, and adequate postoperative CT were included. After postoperative imaging, correlations among clinical and histological characteristics and preoperative imaging were evaluated.

Results

Among the 123 patients who underwent pancreaticoduodenectomy, 48 patients had sufficient follow-up imaging and were included in this study. A total of 33 patients experienced local early recurrence (Group 1), and 15 exhibited no local recurrence (Group 2). Local recurrence consisted of two types of anomalies: tissue nodules on surgical clips (94 %) and peri-arterial encasement (82 %). On preoperative imaging, the tumor diameter (p = 0.02) and the presence of a venous borderline resectable tumor (p < 0.0001) were predictive of local recurrence.

Conclusions

Tissue nodules on surgical clips and arterial encasement characterize early local recurrence, and nodules and encasement should not be considered common post-operative infiltration. The role of the radiologist is essential to assess the predictive factors of recurrence and to identify early local recurrence.
Literature
1.
go back to reference Zhang Y, Frampton AE, Kyriakides C, et al. (2012) Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol 138:1063–1071CrossRefPubMed Zhang Y, Frampton AE, Kyriakides C, et al. (2012) Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol 138:1063–1071CrossRefPubMed
2.
go back to reference Shimada K, Sakamoto Y, Nara S, et al. (2010) Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 34:1908–1915CrossRefPubMed Shimada K, Sakamoto Y, Nara S, et al. (2010) Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 34:1908–1915CrossRefPubMed
3.
go back to reference Ghaned P, Costello E, Neoptolemos J (2007) Biology and management of pancreatic cancer. Gut 56:1143–1152 Ghaned P, Costello E, Neoptolemos J (2007) Biology and management of pancreatic cancer. Gut 56:1143–1152
4.
go back to reference Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046CrossRefPubMed Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046CrossRefPubMed
5.
go back to reference Delpero JR, Bachellier P, Regenet N, et al. (2014) Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford) 16:20–33CrossRef Delpero JR, Bachellier P, Regenet N, et al. (2014) Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford) 16:20–33CrossRef
6.
8.
go back to reference Fischer R, Breidert M, Keck T, et al. (2012) Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi J Gastroenterol 18:118–121PubMedCentralCrossRefPubMed Fischer R, Breidert M, Keck T, et al. (2012) Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi J Gastroenterol 18:118–121PubMedCentralCrossRefPubMed
9.
go back to reference Peddu P, Quaglia A, Kane PA, Karani JB (2009) Role of imaging in the management of pancreatic mass. Crit Rev Oncol Hematol 70:12–23CrossRefPubMed Peddu P, Quaglia A, Kane PA, Karani JB (2009) Role of imaging in the management of pancreatic mass. Crit Rev Oncol Hematol 70:12–23CrossRefPubMed
10.
go back to reference Arslan A, Buanes T, Geitung JT (2001) Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur J Radiol 38:151–159CrossRefPubMed Arslan A, Buanes T, Geitung JT (2001) Pancreatic carcinoma: MR, MR angiography and dynamic helical CT in the evaluation of vascular invasion. Eur J Radiol 38:151–159CrossRefPubMed
11.
go back to reference Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB (2006) The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 20:365–382CrossRefPubMed Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB (2006) The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 20:365–382CrossRefPubMed
12.
go back to reference O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. (2014) A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148PubMedCentralCrossRefPubMed O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. (2014) A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg 260:142–148PubMedCentralCrossRefPubMed
13.
go back to reference Neoptolemos J, Büchler M, Stocken D (2009) ESPAC-3: a multicenter, international, open label, randomized, controlled phase III trial of adjuvant 5fluorouracil/folinic acid vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27:LBA4505 Neoptolemos J, Büchler M, Stocken D (2009) ESPAC-3: a multicenter, international, open label, randomized, controlled phase III trial of adjuvant 5fluorouracil/folinic acid vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27:LBA4505
14.
go back to reference Oettle H, Post S, Neuhaus P, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277CrossRefPubMed Oettle H, Post S, Neuhaus P, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277CrossRefPubMed
15.
go back to reference Neoptolemos JP, Stocken DD, Friess H, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed Neoptolemos JP, Stocken DD, Friess H, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed
16.
go back to reference Strobel O, Hartwig W, Hackert T, et al. (2013) Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20:964–972CrossRefPubMed Strobel O, Hartwig W, Hackert T, et al. (2013) Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 20:964–972CrossRefPubMed
17.
go back to reference Katz MH, Pisters PW, Lee JE, Fleming JB (2011) Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 18:608–610CrossRefPubMed Katz MH, Pisters PW, Lee JE, Fleming JB (2011) Borderline resectable pancreatic cancer: what have we learned and where do we go from here? Ann Surg Oncol 18:608–610CrossRefPubMed
18.
go back to reference Balzano G, Bassi C, Zerbi A, et al. (1997) Evaluation of UICC TNM classification for pancreatic cancer. A study of 228 patients. Int J Pancreatol 21:111–118CrossRefPubMed Balzano G, Bassi C, Zerbi A, et al. (1997) Evaluation of UICC TNM classification for pancreatic cancer. A study of 228 patients. Int J Pancreatol 21:111–118CrossRefPubMed
19.
go back to reference Obuchi T, Sasaki A, Shimooki O, et al. (2009) Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy. Gan To Kagaku Ryoho 36:991–994PubMed Obuchi T, Sasaki A, Shimooki O, et al. (2009) Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy. Gan To Kagaku Ryoho 36:991–994PubMed
20.
go back to reference Miyazaki M, Yoshitomi H, Shimizu H, et al. (2014) Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery 155:58–66CrossRefPubMed Miyazaki M, Yoshitomi H, Shimizu H, et al. (2014) Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery 155:58–66CrossRefPubMed
21.
go back to reference Kinoshita H, Yamade N, Nakai H, et al. (2011) Successful resection of pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy. Hepatogastroenterology 58:1406–1408CrossRefPubMed Kinoshita H, Yamade N, Nakai H, et al. (2011) Successful resection of pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy. Hepatogastroenterology 58:1406–1408CrossRefPubMed
22.
go back to reference Garcea G, Dennison AR, Ong SL, et al. (2007) Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 33:892–897CrossRefPubMed Garcea G, Dennison AR, Ong SL, et al. (2007) Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 33:892–897CrossRefPubMed
23.
go back to reference Katz MH, Wang H, Balachandran A, et al. (2012) Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16:68–78CrossRefPubMed Katz MH, Wang H, Balachandran A, et al. (2012) Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16:68–78CrossRefPubMed
24.
go back to reference Katz MH, Wang H, Fleming JB, et al. (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16:836–847PubMedCentralCrossRefPubMed Katz MH, Wang H, Fleming JB, et al. (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16:836–847PubMedCentralCrossRefPubMed
25.
go back to reference Tachezy M, Gebauer F, Petersen C, et al. (2014) Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 14:411PubMedCentralCrossRefPubMed Tachezy M, Gebauer F, Petersen C, et al. (2014) Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 14:411PubMedCentralCrossRefPubMed
26.
go back to reference Evans DB, Erickson BA, Ritch P (2010) Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol 17:2803–2805CrossRefPubMed Evans DB, Erickson BA, Ritch P (2010) Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Ann Surg Oncol 17:2803–2805CrossRefPubMed
27.
go back to reference John BJ, Naik P, Ironside A, et al. (2013) Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford) 15:674–680CrossRef John BJ, Naik P, Ironside A, et al. (2013) Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford) 15:674–680CrossRef
28.
go back to reference Lee SR, Kim HO, Son BH, Yoo CH, Shin JH (2013) Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma. Hepato gastroenterol 60:358–362 Lee SR, Kim HO, Son BH, Yoo CH, Shin JH (2013) Prognostic factors associated with long-term survival and recurrence in pancreatic adenocarcinoma. Hepato gastroenterol 60:358–362
29.
go back to reference Wentz SC, Zhao Z-G, Shyr Y, et al. (2012) Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol 4:207–215PubMedCentralCrossRefPubMed Wentz SC, Zhao Z-G, Shyr Y, et al. (2012) Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol 4:207–215PubMedCentralCrossRefPubMed
30.
go back to reference Esposito I, Kleeff J, Bergmann F, et al. (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660CrossRefPubMed Esposito I, Kleeff J, Bergmann F, et al. (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660CrossRefPubMed
Metadata
Title
CT imaging of early local recurrence of pancreatic adenocarcinoma following pancreaticoduodenectomy
Authors
Clémence Balaj
Ahmet Ayav
Alexandre Oliver
François Jausset
Caroline Sellal
Michel Claudon
Valérie Laurent
Publication date
01-02-2016
Publisher
Springer US
Published in
Abdominal Radiology / Issue 2/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-015-0564-z

Other articles of this Issue 2/2016

Abdominal Radiology 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine